MedTrace Logo

Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia

NCT00462787 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2013-11-14

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as clofarabine, topotecan, vinorelbine, thiotepa, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.

PURPOSE: This phase I trial is studying the side effects and best dose of clofarabine when given together with topotecan, vinorelbine, thiotepa, and dexamethasone in treating young patients with relapsed or refractory acute leukemia.

Conditions

Interventions

BIOLOGICAL

filgrastim

DRUG

clofarabine

DRUG

dexamethasone

DRUG

thiotepa

DRUG

topotecan hydrochloride

DRUG

vinorelbine tartrate

Sponsors & Collaborators

Principal Investigators

  • Peter G. Steinherz, MD · Memorial Sloan Kettering Cancer Center

  • Neerav Shukla, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
28 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00462787 on ClinicalTrials.gov